• Veru Inc VERU.OQ reported a quarterly adjusted loss of 6 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -8 cents. The mean expectation of five analysts for the quarter was for a loss of 8 cents per share. Wall Street expected results to range from -9 cents to -6 cents per share.

• Reported revenue was zero​; analysts expected $3.02 million.

• Veru Inc's reported EPS for the quarter was a loss of 6 cents​.

• The company reported a quarterly loss of $8.95 million.

• Veru Inc shares had fallen by 15.4% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 1.3% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Veru Inc is $3.00

This summary was machine generated from LSEG data February 13 at 02:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)